Announcement on Subsidiary Obtaining Notice of Approval for Drug Clinical Trials
Release time:
2021-05-20
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No: pro 2020-018
Zhejiang Jianfeng Group Co., Ltd.
Announcement on Subsidiaries Obtaining Notice of Approval for Drug Clinical Trials
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
Important Note:
- Company's approval notice for drug clinical trials will not have a significant impact on the company's recent operating results.
- Risk Warning: Due to the particularity of drug research and development, the pre-development of drugs and the long cycle and many links of products from development, clinical trials to production are susceptible to some uncertain factors, clinical trial progress, There are many uncertainties in the results and the future product market competition situation.
1. Summary
Recently, Zhejiang Jianfeng Yien Biotechnology Co., Ltd. (hereinafter referred to as "Jianfeng Yien") , , a holding subsidiary of Zhejiang Jianfeng Pharmaceutical Co., Ltd., the company's holding subsidiary, received the "Drug Clinical Trial Approval Notice" approved and issued by the State Food and Drug Administration, "JFAN-1001 Capsule, Notice No: 2020LP00246 " and "JFAN-1001 Capsules, Notification No: 2020LP00247 ". The relevant details are hereby announced as follows:
2. drug basic information content
drug name: JFAN-1001 capsule
English name: JFAN-1001Capsule
dosage form: capsule
application item: clinical research application
specification: 10mg , 30mg
registration classification: chemical drugs category
applicant: Zhejiang Jianfeng yien biotechnology co., ltd
approval conclusion: "according to the the People's Republic of China drug administration law and relevant regulations, after examination, 2020 6 February 7 accepted JFAN-1001 glue capsule meets the relevant requirements of drug registration and agrees to carry out clinical trials according to the submitted plan."
3. Drug Research and Development and Registration
JFAN-1001 is a new anti-tumor drug developed by Jianfeng Yien. The registration classification belongs to chemical drug 1 . Jianfeng Yien first submitted JFAN-1001 clinical trial application and was accepted on 2020 6 January 7 (acceptance numbers: CXHL2000255 , CXHL2000256 ). JFAN-1001 is a small molecule antineoplastic agent with indications for EGFR-T790M secondary mutation-positive locally advanced or metastatic non-squamous non-small cell lung cancer. As of the date of this announcement, the accumulated research and development expenses and technical investment of the project totaled about 4676.04 .03 million yuan.
Market Situation of Similar Drugs in 4.
Currently, targeted drugs for epidermal growth factor receptor (EGFR ) inhibitors listed in China include: the first generation EGFR inhibitors include gefitinib, erlotinib and icotinib; The second generation EGFR inhibitors include afatinib and dacotinib; the third generation EGFR inhibitor includes AstraZeneca's osimertinib, which was approved for listing in the United States on November 11, 2009, , , , and approved for listing in China on March 122, , 2017, . AstraZeneca global annual sales of osimertinib in 2019, , .7 billion (source: 2019# AstraZeneca Annual Financial Statement for 129), almetinib of Jiangsu Haosen Pharmaceutical Co., Ltd. was approved to be listed in China in January , March this year. The company's JFAN-1001 is the third generation EGFR inhibitor with the same target as osimertinib, at present, similar drugs in the clinical research stage include efitinib of Shanghai Alex pharmaceutical technology co., ltd., avetinib of Hangzhou essen pharmaceutical research co., ltd., Nanjing shenghe pharmaceutical co., ltd. SH-1028 , Jiangsu osaikang pharmaceutical co., ltd. ASK120067 , Jiangsu runxin biotechnology co., ltd. RX518 and many other enterprises. Approval Procedure for 5. Products to Be Listed Jianfeng Yien will conduct clinical trials according to the requirements of the Notice of Approval of Drug Clinical Trials. After the clinical trials are completed, production will be declared. Production and marketing can only be carried out after passing the review and approval of the State Food and Drug Administration and obtaining the approval documents for drug production. 6. Impact on Listed Companies and Risk Tips
The company's approval notice for drug clinical trials will not have a significant impact on the company's recent operating results. Due to the particularity of drug research and development, the pre-development of drugs and the long cycle and many links from development, clinical trials to production of products are easily affected by some uncertain factors. There are many uncertainties in the progress and results of clinical trials and the future product market competition situation. The company will be based on the progress of research and development in a timely manner to fulfill the obligations of information disclosure, so that the majority of investors pay attention to investment risks.
hereby announce
Zhejiang Jianfeng Group Co., Ltd.
Board of Directors August 19, 2020
More information
Daye Peak Launches Anti-"Three Violations" Special Activities
Recently, Daye Jianfeng Cement Company has set up a special leading group for "anti-three violations" activities headed by Zhang Fengliang, deputy general manager of the group company and general manager of Daye Jianfeng, to vigorously carry out anti-"three violations" activities throughout the plant. Most safety accidents come from illegal command, illegal operation and violation of labor discipline. In order to reduce or even put an end to the phenomenon of "three violations", eradicate persistent diseases in violation of rules and regulations, eliminate hidden dangers of accidents, standardize employees' production safety behavior, and prevent the occurrence of all kinds of production safety accidents, Daye Peak has carried out special activities against "three violations" according to the requirements of the implementation plan of "anti-three violations, accident prevention and safety protection" carried out by the Safety Committee of Baoan Town. The purpose is to strengthen employees' understanding of the harmfulness, make safety education and training more targeted, make the implementation of safety rules and regulations more in place, improve employees' awareness of safety production and safety skills, avoid personal injury accidents, misoperation accidents and other liability accidents caused by violations, and effectively achieve safety production standardization Anti-violation, procedural accident prevention, standardization to ensure safety, and fully achieve the 2016 safety production work goal. According to the plan, this activity is divided into three stages: the first stage is from September 1 to September 15, which is the mobilization and deployment stage; the second stage is from September 16 to October 15, which is the implementation stage; the third stage is from October 16 to October 20, which is the summary and improvement stage. The activities mainly carried out self-examination of "anti-three violations" by hanging safety slogans and banners, and organized the study of safety regulations such as "100 typical violations of production safety" and "post safety operation procedures".
2020
07-31
Daye Peak Launches Anti-"Three Violations" Special Activities
Recently, Daye Jianfeng Cement Company has set up a special leading group for "anti-three violations" activities headed by Zhang Fengliang, deputy general manager of the group company and general manager of Daye Jianfeng, to vigorously carry out anti-"three violations" activities throughout the plant. Most safety accidents come from illegal command, illegal operation and violation of labor discipline. In order to reduce or even put an end to the phenomenon of "three violations", eradicate persistent diseases in violation of rules and regulations, eliminate hidden dangers of accidents, standardize employees' production safety behavior, and prevent the occurrence of all kinds of production safety accidents, Daye Peak has carried out special activities against "three violations" according to the requirements of the implementation plan of "anti-three violations, accident prevention and safety protection" carried out by the Safety Committee of Baoan Town. The purpose is to strengthen employees' understanding of the harmfulness, make safety education and training more targeted, make the implementation of safety rules and regulations more in place, improve employees' awareness of safety production and safety skills, avoid personal injury accidents, misoperation accidents and other liability accidents caused by violations, and effectively achieve safety production standardization Anti-violation, procedural accident prevention, standardization to ensure safety, and fully achieve the 2016 safety production work goal. According to the plan, this activity is divided into three stages: the first stage is from September 1 to September 15, which is the mobilization and deployment stage; the second stage is from September 16 to October 15, which is the implementation stage; the third stage is from October 16 to October 20, which is the summary and improvement stage. The activities mainly carried out self-examination of "anti-three violations" by hanging safety slogans and banners, and organized the study of safety regulations such as "100 typical violations of production safety" and "post safety operation procedures".
2020
07-31
The water and soil conservation scheme of Daye Peak Mine passed the review.
The water and soil conservation plan of Jinshan limestone mine and Baiyunsi sand shale mine of Daye Peak Cement Company passed expert review a few days ago. In order to effectively prevent and control soil erosion, protect and rationally utilize water and soil resources, reduce water, drought, wind and sand disasters, and improve the ecological environment, in accordance with the "the People's Republic of China Soil and Water Conservation Law", "Management Measures for Soil and Water Conservation Programs for Development and Construction Projects" and other laws and regulations Relevant technical specifications and the requirements of local management departments, Daye Peak commissioned Daye City Soil and Water Conservation Test Station in May this year to prepare soil and water and soil and soil conservation plans for Jinshan limestone mine. Recently, the water and soil conservation plans of the two mines have been prepared and reviewed by experts. After nearly a day of careful review, the participating experts and leaders gave a high evaluation of the plan, and put forward some suggestions and opinions for improvement. At the same time, they fully affirmed Daye Peak's attitude of attaching great importance to the work of soil and water conservation in the mine, and unanimously agreed that the above two The plan passed the review. The service life of water and soil conservation scheme of Jinshan Limestone Mine and Baiyunsi Sand Shale Mine is 5 years. In the next five years, Daye Peak will entrust water and soil conservation supervision and monitoring, and gradually organize the implementation of prevention and control measures in accordance with the plan. By 2021, Daye Peak will prepare a technical evaluation report based on the implementation of the water and soil conservation plan, check the construction and implementation of responsibilities, evaluate the effect of soil erosion prevention and control, and apply for completion acceptance. (Daye Peak)
2020
07-31
Daye Peak Launches Anti-"Three Violations" Special Activities
Recently, Daye Jianfeng Cement Company has set up a special leading group for "anti-three violations" activities headed by Zhang Fengliang, deputy general manager of the group company and general manager of Daye Jianfeng, to vigorously carry out anti-"three violations" activities throughout the plant. Most safety accidents come from illegal command, illegal operation and violation of labor discipline. In order to reduce or even put an end to the phenomenon of "three violations", eradicate persistent diseases in violation of rules and regulations, eliminate hidden dangers of accidents, standardize employees' production safety behavior, and prevent the occurrence of all kinds of production safety accidents, Daye Peak has carried out special activities against "three violations" according to the requirements of the implementation plan of "anti-three violations, accident prevention and safety protection" carried out by the Safety Committee of Baoan Town. The purpose is to strengthen employees' understanding of the harmfulness, make safety education and training more targeted, make the implementation of safety rules and regulations more in place, improve employees' awareness of safety production and safety skills, avoid personal injury accidents, misoperation accidents and other liability accidents caused by violations, and effectively achieve safety production standardization Anti-violation, procedural accident prevention, standardization to ensure safety, and fully achieve the 2016 safety production work goal. According to the plan, this activity is divided into three stages: the first stage is from September 1 to September 15, which is the mobilization and deployment stage; the second stage is from September 16 to October 15, which is the implementation stage; the third stage is from October 16 to October 20, which is the summary and improvement stage. The activities mainly carried out self-examination of "anti-three violations" by hanging safety slogans and banners, and organized the study of safety regulations such as "100 typical violations of production safety" and "post safety operation procedures".
2020
07-30
Spike Pharmaceuticals Enters Infant Drug Market
Jindal Baby Drug Co., Ltd. Established Peak Pharmaceuticals to Enter Infant Drug Market Recently, Zhejiang Jindal Baby Drug Co., Ltd., a Sino-German joint venture controlled by Peak Pharmaceuticals, completed registration. Peak Pharmaceuticals will use this as a basis to introduce German technology and products and develop the infant drug market. Zhejiang Jindel Baby Drug Co., Ltd. was jointly funded by Jianfeng Pharmaceutical, Germany Gefu Pharmaceutical Co., Ltd. and Zhuhai Hengqin Deyunjia International Trade Co., Ltd., with a registered capital of 20 million yuan, of which Jianfeng Pharmaceutical contributed 11 million yuan in cash, accounting for 55% of the registered capital. Gefu Pharmaceuticals invested 5 million yuan in the evaluation of two proprietary technologies of "diazepam suppository" and "acetaminophen suppository, 25% of the registered capital; De Yunjia contributed 4 million yuan in cash, accounting for 20% of the registered capital. The company's registered address is in Jinxi Development Zone, Jinhua City. It will rent the existing factory building of Jianfeng Pharmaceutical Jinxi Pharmaceutical Factory for renovation, and strive to absorb their respective expertise and adopt appropriate advanced technology and scientific management methods. A modern pharmaceutical enterprise focusing on the research and development, production and sales of pharmaceutical preparations for infants and children. In this cooperation, the corresponding products of "diazepam suppository" and "acetaminophen suppository", which Ge Fu pharmaceutical has invested in with proprietary technology evaluation, have been listed in Germany, among which diazepam suppository is a therapeutic drug for anti-anxiety, sleep disorder and muscle tension increase; acetaminophen is used for fever caused by cold or cold, and also for relieving mild to moderate pain. After the establishment of the joint venture company, it will be based on these two know-how.
2020
07-31
Jinhua City People's Congress Leaders Peak Survey
On July 26, Cai Jian, deputy director of the Jinhua Municipal People's Congress, Chen Zhishi, secretary general of the Standing Committee of the National People's Congress, and a group of four people visited Jianfeng to conduct research on the introduction of talents and technological innovation, and to communicate with Jiang Xiaomeng, Yu Jianhong, Huang Jinlong, Xiang Chongping, Lan Xiaolong and other group company leaders conducted in-depth exchanges. (this newspaper reporter)
2020
07-31